

SEP 18 2007

Application No. 10/690,992  
Amendment dated September 18, 2007

2

Docket No.: 60130(71987)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for ~~obtaining~~ preparing an extract from *Bupleurum scorzonerifolium*, ~~wherein the extract comprises antineoplastic components, comprising the steps of:~~  
dissolving *Bupleurum scorzonerifolium* powder using an acetone solution to obtain an acetone extract and residues;

dissolving the acetone extract in a protic solvent solution and extracting the protic solvent solution with a nonpolar organic solvent, to obtain a nonpolar organic solvent extract and a protic solvent portion; and

dissolving the protic solvent portion in an aqueous solvent and extracting with a polar organic solvent to obtain a polar organic solvent extract comprising antineoplastic components and an aqueous portion.

2. (Canceled)

3. (Previously presented) The method of claim 1, wherein the protic solvent solution is 95% methanol/5% water.

4. (Previously presented) The method of claim 1, wherein the aqueous solvent is water.

5. (Previously presented) The method of claim 1, wherein the nonpolar organic solvent is hexane.

6. (Previously presented) The method of claim 1, wherein the polar organic solvent is chloroform.

7-11. (Canceled)

Application No. 10/690,992  
Amendment dated September 18, 2007

3

Docket No.: 60130(71987)

12. (Previously presented) The method of claim 1, wherein the antineoplastic components have anti-tumor effects on hepatoma.

13. (Previously presented) The method of claim 1, wherein the antineoplastic components have anti-tumor effects on ovarian cancer.

14. (Previously presented) The method of claim 1, wherein the antineoplastic components have anti-tumor effects on malignant glioblastoma.


15. (Previously presented) The method of claim 1, wherein the antineoplastic components have anti-tumor effects on lung cancer.

16. (Previously presented) The method of claim 1, wherein the antineoplastic components have anti-tumor effects on colorectal cancer.

17. (Previously presented) The method of claim 1, wherein the antineoplastic components have anti-tumor effects on tumors which are resistant to a taxane-type anticancer agent.

18. (Original) The method of claim 17, wherein the taxane-type anticancer agent is Paclitaxel.

19. (Withdrawn) The method of claim 1, wherein the antineoplastic components comprise at least one of the following heterocyclic compounds or pharmacologically compatible salts, esters, ketones or derivatives based on the following formula:




Application No. 10/690,992  
Amendment dated September 18, 2007

4

Docket No.: 60130(71987)

wherein X includes N, O, S, and Se.


20. (Withdrawn) The method of claim 19, wherein A, B substituents can be selected from the following substituent structures:



21. (Withdrawn) The method of claim 19, wherein the heterocyclic compounds have a Z configuration at a carbon 2(5) position.

22. (Withdrawn) The method of claim 19, wherein the heterocyclic compounds have a E configuration at a carbon 2(5) position.

23. (Withdrawn) The method of claim 19, wherein the heterocyclic compound having the following formula is named chaihulactone:




where R represents a methoxyl group.

Application No. 10/690,992  
Amendment dated September 18, 2007

5

Docket No.: 60130(71987)

24. (Previously presented) The method of claim 1, wherein the antineoplastic components comprise a compound having the following formula:



where R represents a hydrogen atom, a methoxyl group, or an aromatic group.

25. (Previously presented) The method of claim 1, wherein the antineoplastic components arrest a G2/M stage of a cell cycle.

26. (Previously presented) The method of claim 1, wherein the antineoplastic components stabilize a microtubule.

27. (Previously presented) The method of claim 1, wherein the antineoplastic components are used in conjunction with an anti-tumor drug.

28. (Previously presented) The method of claim 27, wherein the anti-tumor drug is Cisplatin.

29. (Previously presented) The method of claim 27, wherein the anti-tumor drug is Taxol.

30. (Previously presented) The method of claim 1, wherein the antineoplastic components down-regulate human telomerase reverse transcriptase (hTERT) gene.

31. (Previously presented) The method of claim 30, wherein the antineoplastic components down regulate hTERT gene in human immunodeficiency virus (HIV).

Application No. 10/690,992  
Amendment dated September 18, 2007

6

Docket No.: 60130(71987)

32. (Previously presented) The method of claim 1, wherein the antineoplastic components inhibit telomerase activity.

33. (Previously presented) The method of claim 32, wherein the antineoplastic components inhibit telomerase activity in HIV.